Z. Malik Et Al. , "Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).," Genitourinary Cancers Symposium , vol.32, San-Francisco, Costa Rica, 2014
Malik, Z. Et Al. 2014. Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. Genitourinary Cancers Symposium , (San-Francisco, Costa Rica).
Malik, Z., di Lorenzo, G., Bracarda, S., Ardavanis, A., Basaran, M., Parente, P., ... de Schultz, W.(2014). Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). . Genitourinary Cancers Symposium, San-Francisco, Costa Rica
Malik, Zafar Et Al. "Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).," Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 2014
Malik, Zafar Et Al. "Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).." Genitourinary Cancers Symposium , San-Francisco, Costa Rica, 2014
Malik, Z. Et Al. (2014) . "Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).." Genitourinary Cancers Symposium , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={Zafar Malik Et Al. }, title={Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).}, congress name={Genitourinary Cancers Symposium}, city={San-Francisco}, country={Costa Rica}, year={2014}}